Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Cash from Financing Activities: 2023-2025

  • Inhibrx Biosciences' Cash from Financing Activities was N/A to $352,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $171.9 million, marking a year-over-year change of. This contributed to the annual value of $71.7 million for FY2024, which is 64.51% down from last year.
  • Inhibrx Biosciences' Cash from Financing Activities amounted to $352,000 in Q3 2025, which was down 99.65% from $99.8 million recorded in Q1 2025.
  • In the past 5 years, Inhibrx Biosciences' Cash from Financing Activities ranged from a high of $199.9 million in Q3 2023 and a low of $352,000 during Q3 2025.
  • Over the past 3 years, Inhibrx Biosciences' median Cash from Financing Activities value was $35.8 million (recorded in 2024), while the average stood at $62.1 million.
  • Data for Inhibrx Biosciences' Cash from Financing Activities shows a peak YoY skyrocketed of 157.80% (in 2025) over the last 5 years.
  • Over the past 3 years, Inhibrx Biosciences' Cash from Financing Activities (Quarterly) stood at $860,000 in 2023, then reached $33.0 million in 2024, then skyrocketed by 157.80% to $352,000 in 2025.
  • Its Cash from Financing Activities stands at $352,000 for Q3 2025, versus $99.8 million for Q1 2025 and $33.0 million for Q2 2024.